Vimarsana
Biggest News Aggregation in the World

Page 37 - Confidence Interval News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Confidence Interval. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Confidence Interval Today - Breaking & Trending Today

Endotrophin Levels Could Signal Elevated Kidney Risk in Type 1 Diabetes - Vimarsana News

Endotrophin Levels Could Signal Elevated Kidney Risk in Type 1 Diabetes

Elevated serum endotrophin levels, but not urinary endotrophin levels, predict increased risk of kidney complications and mortality in type 1 diabetes.

Pegozafermin associated with improved outcomes in nonalcoholic steatohepatitis - Vimarsana News

Pegozafermin associated with improved outcomes in nonalcoholic steatohepatitis

1. In this randomized controlled trial, treatment with pegozafermin improved fibrosis in patients with nonalcoholic steatohepatitis (NASH). 2. Treatment with pegozafermin led to increased rates of NASH resolution. Evidence Rating Level: 1 (Excellent) Study Rundown: NASH is a disease characterized by hepatic inflammation and excess fat accumulation with or without fibrosis of the liver. Pegozafermin

Low achievement of guideline-recommended diabetes targets in Chinese adults - Vimarsana News

Low achievement of guideline-recommended diabetes targets in Chinese adults

1. In this cross-sectional study, the proportion of Chinese adults with self-reported type 2 diabetes who achieved a guideline-recommended HbA1c target was 64.1%. 2. The proportion of Chinse adults with self-reported type 2 diabetes who achieved a guideline-recommended blood pressure was 22.2%. Evidence Rating Level: 1 (Excellent) Study Rundown: More than one-quarter of the Chinese

Generic and brand-name fluticasone-salmeterol are equally effective in COPD management - Vimarsana News

Generic and brand-name fluticasone-salmeterol are equally effective in COPD management

1. In this cohort study, using generic versus brand-name fluticasone-salmeterol was associated with similar outcomes in chronic obstructive pulmonary disease (COPD) patients. 2. Using generic versus brand-name fluticasone-salmeterol was associated with no significant difference in the incidence of COPD exacerbations or pneumonia hospitalizations. Evidence Rating Level: 1 (Excellent) Study Rundown: Chronic obstructive pulmonary disease is

Adjunctive antidepressant maintenance ineffective in bipolar I depression - Vimarsana News

Adjunctive antidepressant maintenance ineffective in bipolar I depression

1. In this randomized controlled trial, adjunctive treatment with escitalopram or bupropion XL for 52 weeks was not superior to eight weeks in preventing relapse of mood episodes among patients with bipolar I depression. 2. The rates of adverse events were comparable across both approaches. Evidence Rating Level: 2 (Good) Study Rundown: Bipolar I disorder